🌍 Global Problem. Scalable Solution

Skin cancer is one of the most rapidly rising cancers worldwide, with millions of new cases annually. Despite this, access to early and painless diagnostics remains very limited. DermaEye bridges this gap with a scalable, real-time solution that fits seamlessly into dermatology clinics, hospitals, and telehealth setups.

💡Why Invest in Livvolta?

• Deep-Tech Innovation: AI + MSI + HFUS platform with global patent strategy.

• Validated Market: Addressing a $12–15 billion global market with high CAGR.

• Dual Use Cases: Developed for both developed markets (US, Europe) and high-growth regions (Asia-Pacific, Oceania).

• Strong Team: Backed by industry veterans and expert team.

• Traction: Prototype validated, early grants secured, regulatory planning underway.

📈 Our Growth Roadmap

• 2025–2026: Product refinement, CDSCO clearance, clinical pilots ,  Sales in INDIA

• 2027: Entry into North American markets; FDA/Health Canada approval pathway.

• 2028+: Asia-Pacific expansion via Singapore; scale through strategic B2B and telehealth partners.

🤝 Join Us as a Strategic Investor

We are seeking visionary investors who share our belief in accessible, high-impact healthcare. Join us in this early stage and be a part of our journey to revolutionize the field of Dermatology worldwide. Strategic investments will accelerate:

• Product development

• Regulatory approval

• Clinical validation

• Global market penetration

Interested in Partnering With Us? 

Fill out the form below and our team will get in touch with you shortly.